TLSI vs DBVT vs HALO vs REGN vs MRK

For growth investors, TriSalus Life Sciences, Inc.

(TLSI) is the stronger pick with 53. 4% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 4x trailing P/E (21. 7x forward), making it the more compelling value choice. Analysts rate TriSalus Life Sciences, Inc. (TLSI) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 4x versus Halozyme Therapeutics, Inc. at 25. 5x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Halozyme Therapeutics, Inc. wins at 0. 35x versus Regeneron Pharmaceuticals, Inc. 's 2. 44x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Merck & Co.

, Inc. (MRK) delivered a total return of +70. 2%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: HALO returned +559. 7% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merck & Co.

, Inc. (MRK) is the lower-risk stock at 0. 45β versus TriSalus Life Sciences, Inc. 's 1. 36β — meaning TLSI is approximately 200% more volatile than MRK relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 96% for Merck & Co. , Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TriSalus Life Sciences, Inc.

(TLSI) is pulling ahead at 53. 4% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Regeneron Pharmaceuticals, Inc. grew EPS 8. 2% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, TLSI leads at 53. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -154. 3% for TriSalus Life Sciences, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -59. 7% for TLSI. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Halozyme Therapeutics, Inc. (HALO) is the more undervalued stock at a PEG of 0. 35x versus Regeneron Pharmaceuticals, Inc. 's 2. 44x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Halozyme Therapeutics, Inc. (HALO) trades at 8. 0x forward P/E versus 21. 7x for Merck & Co. , Inc. — 13. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TLSI: 135. 4% to $10. 50.

In this comparison, MRK (2.

9% yield), REGN (0. 5% yield) pay a dividend. TLSI, DBVT, HALO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), 2. 9% yield, +164. 7% 10Y return). Both have compounded well over 10 years (MRK: +164. 7%, TLSI: -57. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TLSI is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; HALO is a small-cap high-growth stock; REGN is a mid-cap deep-value stock; MRK is a large-cap deep-value stock. MRK pays a dividend while TLSI, DBVT, HALO, REGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.